UNDERSTAND THAT WE CAN DO MORE THAN DIALYSIS

WHICH INNOVATIVE SOLUTIONS ARE IMPORTANT TO OUR PATIENTS

THAT WE HAVE SET THE COURSE FOR A SUCCESSFUL FUTURE

How we further strengthen our market position and generate profitable growth

WHAT COUNTS

FRESENIUS MEDICAL CARE

2015
ABOUT FOUR DECADES OF EXPERIENCE, INNOVATIVE RESEARCH, THE GLOBAL LEADER IN DIALYSIS SERVICES AND PRODUCTS – THAT IS FRESENIUS MEDICAL CARE.

CREATING A FUTURE WORTH LIVING. FOR PATIENTS. WORLDWIDE. EVERY DAY.
Patients with kidney disease can now look ahead with much more confidence thanks to our innovative technologies and treatment concepts. We give them a future, one that offers them the best possible quality of life. We use the increasing demand for modern dialysis methods to our advantage and work consistently to enhance the Company’s growth perspectives. Together with our employees, we focus on pursuing strategies that will enable us to uphold our technological leadership. As a vertically integrated company, we offer products and services for the entire dialysis value chain.

The highest medical standards are our benchmark. This is our commitment to our patients, our partners in the health care system and our investors, who trust in the reliable performance and the future of Fresenius Medical Care.
“We can only offer the best care if we truly understand our patients, our business and the markets in which we operate.”
Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure.

104,033

Employees 2015

37

Production sites worldwide

16,738

Revenue 2015 in $M
DIALYSIS

is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure.

As a vertically integrated company, Fresenius Medical Care offers products and services along the entire dialysis value chain from a single source.

Along with our core business, we will focus on expanding our range of additional medical services.

44,596,446
dialysis treatments in 2015

Through our network of dialysis clinics we provide treatment for

294,381
patients.

AROUND

2.8 M

PATIENTS WORLDWIDE REGULARLY RECEIVE A DIALYSIS TREATMENT.
Every 0.7 seconds, we treat a patient with dialysis somewhere in the world.

WE OPERATE
3,418
DIALYSIS CENTERS
IN MORE THAN 45 COUNTRIES
WORLDWIDE.

ONE IN TWO DIALYSIS MACHINES WORLDWIDE IS MADE BY FRESENIUS MEDICAL CARE.
Fresenius Medical Care provides more people than ever with access to life-saving dialysis therapies. We will keep on working to expand our core business with dialysis products and the treatment of dialysis patients.

Along with strong growth in our core business, we aim to expand our range of additional medical services, the so-called Care Coordination business. Trust in the quality of our products and services makes us a reliable partner for patients, health care systems and investors.
**WE PROVIDE**

**DIALYSIS PRODUCTS**

- Peritoneal Dialysis (PD)
- Hemodialysis (HD)

**DIALYSIS SERVICES**

*Fresenius Medical Care is the leading provider of dialysis services treating 294,381 patients in 2015.*

**CARE COORDINATION**

1. **Vascular Surgery**
2. **Pharmaceuticals Distribution**
3. **Laboratory Testing Services**
4. **Urgent Care Services**
5. **Health Plan Services**
6. **Hospitalist and Intensivist Services**

*The patient comes first.*
## Revenue

<table>
<thead>
<tr>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>16,738</td>
<td>15,832</td>
</tr>
</tbody>
</table>

(Change of 6%)

## Operating Income (EBIT) in $M

<table>
<thead>
<tr>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,387</td>
<td>2,255</td>
</tr>
</tbody>
</table>

(Change of 6%)

## Net Income

<table>
<thead>
<tr>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,066</td>
<td>1,045</td>
</tr>
</tbody>
</table>

(Change of 2%)

## Basic Earnings Per Share in $M

<table>
<thead>
<tr>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.49</td>
<td>3.46</td>
</tr>
</tbody>
</table>

(Change of 1%)

## Selected Key Figures in $M

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings before interest, taxes, depreciation and amortization (EBITDA)</td>
<td>3,044</td>
<td>2,954</td>
</tr>
<tr>
<td>Net cash provided by (used in) operating activities</td>
<td>1,960</td>
<td>1,861</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>1,025</td>
<td>941</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>935</td>
<td>920</td>
</tr>
<tr>
<td>Acquisitions and investments, net</td>
<td>66</td>
<td>1,770</td>
</tr>
<tr>
<td>Operating income margin in %</td>
<td>13.9</td>
<td>14.2</td>
</tr>
<tr>
<td>Return on invested capital (ROIC) in %</td>
<td>6.9</td>
<td>6.9</td>
</tr>
<tr>
<td>Equity ratio (equity/total assets)</td>
<td>41.1</td>
<td>39.5</td>
</tr>
</tbody>
</table>

1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.
2 Adjusted for the out-of-court settlement in principle in a product liability case (Granuflo).
3 Net cash provided by (used in) operating activities after capital expenditures, before acquisitions and investments.
4 As of December 31 of the respective year.
**Revenue 2015**

16% Europe/Middle East/Africa
9% Asia-Pacific
4% Latin America

16,738 $M

71% North America

**Health Care Services**

5% Asia-Pacific
4% Latin America

13,392 $M

82% North America
17% Care Coordination

**Dialysis Products**

25% Asia-Pacific
1% Corporate
42% Europe/Middle East/Africa

3,346 $M

26% North America
6% Latin America
**PATIENTS**

- **30,200**
  - Latin America
- **26,472**
  - Asia-Pacific
- **54,857**
  - Europe/Middle East/Africa
- **294,381**
  - Total
- **182,852**
  - North America

**TREATMENTS IN M**

- **4.91**
  - Latin America
- **3.79**
  - Asia-Pacific
- **8.21**
  - Europe/Middle East/Africa
- **45**
  - Total
- **27.69**
  - North America

**CLINICS**

- **229**
  - Latin America
- **320**
  - Asia-Pacific
- **659**
  - Europe/Middle East/Africa
- **3,418**
  - Total
- **2,210**
  - North America
CREATING A FUTURE WORTH LIVING.
BE A PART OF IT.

WE AIM:
TO OFFER OUR PATIENTS THE BEST AND SAFEST DIALYSIS PRODUCTS AND HEALTH CARE SERVICES

http://career.freseniusmedicalcare.com

EMPLOYEES BY REGION

- 9% Latin America
- 15% Corporate
- 16% Europe/Middle East/Africa
- 8% Asia-Pacific
- 52% North America

104,033
DIVIDEND PER SHARE IN €

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>0.80</td>
</tr>
<tr>
<td>2014</td>
<td>0.78</td>
</tr>
<tr>
<td>2013</td>
<td>0.77</td>
</tr>
<tr>
<td>2012</td>
<td>0.75</td>
</tr>
<tr>
<td>2011</td>
<td>0.69</td>
</tr>
</tbody>
</table>

1 Proposal to be approved by the Annual General Meeting on May 12, 2016.

SHARE PRICE PERFORMANCE – 5 YEARS IN €

<table>
<thead>
<tr>
<th>Year</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>85</td>
</tr>
<tr>
<td>2012</td>
<td>75</td>
</tr>
<tr>
<td>2013</td>
<td>65</td>
</tr>
<tr>
<td>2014</td>
<td>55</td>
</tr>
<tr>
<td>2015</td>
<td>45</td>
</tr>
</tbody>
</table>

BASIC SHARE DATA

Stock exchanges
Frankfurt Stock Exchange/Prime Standard: FME
New York Stock Exchange (NYSE): FMS
Reuters: XETRA/ADR NYSE: FMEG.DE/FMS.N
Bloomberg: XETRA/ADR NYSE: FME GY/FMS US

Security identification codes
WKN: 578580
ISIN: DE0005785802
CUSIP No. (NYSE): 358029106
FINANCIAL CALENDAR

May 3, 2016
Report on the first quarter 2016

May 12, 2016
Annual General Meeting
Frankfurt am Main, Germany

May 13, 2016
Payment of dividend subject to the approval of the Annual General Meeting

August 2, 2016
Report on the second quarter 2016

October 27, 2016
Report on the third quarter 2016

Subject to change

IMPRINT

FRESENIUS MEDICAL CARE AG & CO. KGAA

Registered seat and commercial register: Hof an der Saale (Germany), HRB 4019

Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Medical Care Management AG

Registered seat and commercial register: Hof an der Saale (Germany), HRB 3894

Management Board:
Rice Powell (Chairman), Michael Brosnan, Roberto Fusté, Ronald Kuerbitz, Dr. Olaf Schermeier, Kent Wanzek, Dominik Wehner

Chairman of the Supervisory Board: Dr. Ulf M. Schneider

EDITORIAL OFFICE
Investor Relations & Corporate Communications

PHOTOGRAPHY
David Magnusson: Cover, 4–5
Matthias Haslauer: 4–5, 8
Matthias Ziegler: 6

CONCEPT AND DESIGN
hw.design gmbh